Navigation Links
Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology

DENVER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced the publication of a research paper on two of the Company's antimicrobial compounds: CSA-8 and CSA-13. The paper appeared in the April issue of the Journal of Antimicrobial Agents and Chemotherapy, a peer-reviewed official Journal of the American Society of Microbiology, dedicated to advances in the field of applied microbiology.

The publication is entitled "Antimicrobial Activities of Ceragenins Against Clinical Isolates of Resistant Staphylococcus Aureus" authored by Drs.Chin, Rybak, Cheung and Savage (Drs. Chin, Rybak and Cheung are researchers at the Anti-Infective Research Laboratory of the Eugene Appelbaum College of Pharmacy and Health Sciences, Wayne State University and Dr. Savage is the Reed Izatt Professor of Chemistry and BioChemistry at Brigham Young University). Dr. Savage is the inventor of the Ceragenin(TM) technology and also serves as a consultant to the Company. The authors highlight the need for development of new antimicrobial compounds to combat the rising incidence of strains of Staphylococcus Aureus that are now resistant to methicillin (MRSA) and vancomycin (VISA, hVISA and VRSA) antibiotics and describe the potent in vitro activity of CSA-8 and CSA-13 against such strains. The authors concluded that:

"Ceragenins are unique, low-molecular-mass compounds that have potent bactericidal activities against both gram-negative and gram-positive bacteria, particularly clinically relevant pathogens such as MRSA .... Both CSA-8 and CSA-13 are promising antimicrobials and may have important therapeutic implications for infections caused by hVISA and VISA strains. Given that these small compounds are experimental antimicrobial agents, future safety, efficacy and pharmokinetic studies in vivo should be performed to cor
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:9/22/2014)... Sept. 22, 2014  AbbVie (NYSE: ... studies evaluating potential new medicines in the company,s ... 2014 European Society of Medical Oncology (ESMO) Annual ... . Data being presented include results from ... efficacy of veliparib (ABT-888), a poly (adenosine diphosphate ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... NEW YORK , Sept. 22, ... has signed an exclusive, global license agreement with ... commercialization of its proprietary plasma fractionation process. Concurrently, ... and its intention to strategically refocus and rebrand ... plans to pursue a national listing for its ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) today reported ... Cash, cash equivalents, and investments at September 30, ... 31, 2010. Revenue for the third quarter of ... in the third quarter of 2010 primarily as a result of ...
... NEW YORK, Nov. 2, 2011 JDRF and The Leona ... largest non-government funders of type 1 diabetes (T1D) programs, announced ... a new level of cooperation between the organizations. The goal ... and development to deliver better treatments, devices, and diagnostics for ...
Cached Medicine Technology:Nektar Therapeutics Reports Third Quarter 2011 Financial Results 2Nektar Therapeutics Reports Third Quarter 2011 Financial Results 3Nektar Therapeutics Reports Third Quarter 2011 Financial Results 4Nektar Therapeutics Reports Third Quarter 2011 Financial Results 5Nektar Therapeutics Reports Third Quarter 2011 Financial Results 6Nektar Therapeutics Reports Third Quarter 2011 Financial Results 7Nektar Therapeutics Reports Third Quarter 2011 Financial Results 8JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 2JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 3JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 4
(Date:9/22/2014)... Severe weather can occur with little warning, so it’s ... of National Preparedness Month, Amica Insurance is offering the ... unexpected:, , Build an emergency supply kit. It ... gallon of water per person per day for at least 72 ... includes pets so your family knows what to do and where ...
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... -- Metformin, a drug commonly used to treat diabetes, ... hormone (TSH) among patients with an underactive thyroid, a ... TSH levels may be associated with heart problems and ... in this study. Among those in the study ... of low levels of thyroid-stimulating hormone per year compared ...
(Date:9/22/2014)... 22, 2014 The report segments ... end user, and geography. The equipment segment accounted ... equipment market, by product. However, the accessories segment ... in the forecast period, owing to the rising ... stimulation and ultrasound segments are the fastest-growing segments ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... 5.6 Onboard Software to Navigate the Safest, Most Fuel-Efficient Route and Protect ... the World,s Poor , ... Sunnyvale, Calif. (Vocus) March 16, 2009 -- ... , the leader in using hospital ships to deliver free, world-class health ...
... making great money is a reality. This year we focus on advancing ... Social Engineering. Spring ChicagoCon 2009 by TDCC features world-class security training followed ... career on the cutting edge of technology and the human mind. ... ...
... harm that often follows brain injury, researcher says, , , ... of Alzheimer,s disease drugs may prevent long-term damage from ... Georgetown University Medical Center researchers. , The drugs -- ... that accumulates in the brains of people with Alzheimer,s ...
... getaway destinations are affected, studies find , , SUNDAY, March 15 ... can be a burden on a family,s finances and even ... be presented in Washington, D.C., at the annual meeting of ... these common conditions can have a wide impact on a ...
... All-In-One Mobility Solutions , ... Blue ... proud to announce the branding of RACO,s Advanced Solutions Group ... area network design, RFID compliance and application software development services ...
... WILMINGTON, Del., March 14 Today AstraZeneca ... in response to the appointment of a new FDA ... Commissioner of the Food and Drug Administration. Dr. Hamburg ... will serve the agency well in these challenging times. ...
Cached Medicine News:Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 4Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 5Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 2Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 3Health News:Alzheimer's Drug May Someday Help Head Trauma Victims 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:RACO Brands Its Advanced Solutions Group 2Health News:AstraZeneca Applauds Appointment of New FDA Commissioner 2
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: